Whether any progress will be made in the immuno-oncology drug Keytruda’s reimbursement journey in the second half of the year is gaining attention. The application, which was first filed for 13 indications, has now grown to request coverage for 17 indications.

In June last year, MSD Korea applied to extend the reimbursement coverage of its PD-1 inhibitor Keytruda (pembrolizumab) to 13 indications

The 13 indications were: ▲ early-stage triple-negative breast cancer; ▲locally recurrent or metastatic triple-negative breast cancer, ▲metastatic or with unresectable, recurrent head and neck squamous cell carcinoma, ▲ locally advanced or metastatic esophageal or gastroesophageal junction (